Aligos therapeutics announces six abstracts accepted for presentation at easl 2024

South san francisco, calif., may 22, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstracts have been accepted for poster presentations, including two top abstracts, at the european association for the study of the liver (easl) congress 2024, being held june 5-8 in milan, italy. the abstracts released today can be found on the easl website at www.easlcongress.eu.
ALGS Ratings Summary
ALGS Quant Ranking